Renting the Molecule Factory: Pierre Fabre, XtalPi and Mid-Sized Pharma's AI Bet
Dr. Dereck Mush, MD, MBA
What they do
Rayca Precision, the University of New Mexico and the University of Arkansas for Medical Sciences announced a three-party co-development agreement on November 10, 2026. The partners aim to identify and evaluate potential therapeutic candidates for cancers associated with high-risk human papillomavirus, combining AI-enabled drug discovery, HPV biology and medicinal chemistry. Pouya Behrouzi is co-founder and CEO. The collaboration is a discovery program, not an approved therapy or a clinical efficacy finding.
People in this update
- Pouya BehrouziCo-founder and CEOSource
The record
- Vertical
- Biotech & Drug Discovery
- Sub-segment
- AI molecular design
- Product type
- Platform software
- Stage
- Headquarters
- Not disclosed
- Region
- Founded
- Not disclosed
- Total funding
- Undisclosed
Also in Biotech & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
Overcoming the Solvent Front: How Jideytro Validates Nuvalent's Precision Oncology Playbook
Dr. Dereck Mush, MD, MBA
Molecular Cardioprotection: How Pediatric Myosin Inhibition Redefines the Economics of Congenital Heart Care
Dr. Dereck Mush, MD, MBA
Precision fermentation is quietly becoming a supply chain strategy for biotech, not just a food tech story
Dr. Dereck Mush, MD, MBA